EYPT – eyepoint pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $30.00 to $22.00. They now have a "buy" rating on the stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $38.00 to $33.00. They now have an "outperform" rating on the stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Chardan Capital from $28.00 to $33.00. They now have a "buy" rating on the stock.
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Form SC 13G/A EyePoint Pharmaceuticals Filed by: Cormorant Asset Management, LP
Form SC 13G/A EyePoint Pharmaceuticals Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SC 13G/A EyePoint Pharmaceuticals Filed by: VANGUARD GROUP INC
Form SC 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
Form SC 13G EyePoint Pharmaceuticals Filed by: BlackRock, Inc.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.